Breakthroughs in Drug Design, Development, and Delivery Systems for the Management of Neuro-Psychiatric Disorders

Abstract: Neuro-psychiatric disorders represent one of the most complex and pressing challenges in modern medicine. These conditions, ranging from schizophrenia and Parkinson’s disease to Alzheimer’s and mood disorders, are characterized by multifactorial etiologies, overlapping symptomatology, and often unpredictable therapeutic responses. Despite decades of research, the pharmacological management of these disorders remains suboptimal, with many patients experiencing limited efficacy, delayed onset of action, or debilitating side effects. A growing body of evidence points to shared pathological mechanisms across neurodegenerative and psychiatric conditions, including intracerebral protein aggregation, mitochondrial dysfunction, abnormal iron accumulation, oxidative stress, and ferroptosis-induced neuronal death. These converging pathways underscore the need for therapeutic strategies that go beyond symptomatic relief to address underlying molecular dysfunctions. In this context, this thematic issue brings together a collection of cutting-edge research articles that reflect the latest advances in drug design, development, and delivery strategies to improve therapeutic outcomes in neuropsychiatric care. This issue is a curated effort to bridge the gap between molecular innovation and clinical translation. It highlights how interdisciplinary approaches spanning medicinal chemistry, pharmacogenomics, molecular docking, and natural product research are converging to redefine the therapeutic landscape. From enzyme-targeted therapies and marine-derived neuroprotectants to prolactin-sparing antipsychotics and precision medicine frameworks, each manuscript contributes a unique perspective to this evolving field. Collectively, these studies illuminate promising avenues for personalized, mechanism-based interventions that may transform the future of neuropsychiatric treatment. This issue aspires to serve not only as a scholarly resource but also as a catalyst for innovation and collaboration across disciplines.

Authors

Institutions

Publication Details

Journal
Current Psychopharmacologye
Published
2026-04-29
DOI
https://doi.org/10.2174/0122115560431816251204142757
Primary Topic
Ferroptosis and cancer prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Breakthroughs in Drug Design, Development, and Delivery Systems for the Management of Neuro-Psychiatric Disorders

Pratap Kumar Sahu, Sunil Kumar Kadiri, Prashant Tiwari
Current Psychopharmacologye
Ferroptosis and cancer prognosis
article

Breakthroughs in Drug Design, Development, and Delivery Systems for the Management of Neuro-Psychiatric Disorders

Pratap Kumar Sahu, Sunil Kumar Kadiri, Prashant Tiwari
article en

Abstract

Abstract: Neuro-psychiatric disorders represent one of the most complex and pressing challenges in modern medicine. These conditions, ranging from schizophrenia and Parkinson’s disease to Alzheimer’s and mood disorders, are characterized by multifactorial etiologies, overlapping symptomatology, and often unpredictable therapeutic responses. Despite decades of research, the pharmacological management of these disorders remains suboptimal, with many patients experiencing limited efficacy, delayed onset of action, or debilitating side effects. A growing body of evidence points to shared pathological mechanisms across neurodegenerative and psychiatric conditions, including intracerebral protein aggregation, mitochondrial dysfunction, abnormal iron accumulation, oxidative stress, and ferroptosis-induced neuronal death. These converging pathways underscore the need for therapeutic strategies that go beyond symptomatic relief to address underlying molecular dysfunctions. In this context, this thematic issue brings together a collection of cutting-edge research articles that reflect the latest advances in drug design, development, and delivery strategies to improve therapeutic outcomes in neuropsychiatric care. This issue is a curated effort to bridge the gap between molecular innovation and clinical translation. It highlights how interdisciplinary approaches spanning medicinal chemistry, pharmacogenomics, molecular docking, and natural product research are converging to redefine the therapeutic landscape. From enzyme-targeted therapies and marine-derived neuroprotectants to prolactin-sparing antipsychotics and precision medicine frameworks, each manuscript contributes a unique perspective to this evolving field. Collectively, these studies illuminate promising avenues for personalized, mechanism-based interventions that may transform the future of neuropsychiatric treatment. This issue aspires to serve not only as a scholarly resource but also as a catalyst for innovation and collaboration across disciplines.

Current PsychopharmacologyeVol. 14
Siksha O Anusandhan University (IN), Dr. Hari Singh Gour University (IN)
Openalex Percentile: Top 7%
Ferroptosis and cancer prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.